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based on the published literature about economic burden of chronic hepatitis B. A 
discounting rate at 3% was used to discount medical costs happened at different years. 
A univariate sensitivity analysis was performed to understand the key drivers and 
general sensitivity of the model. RESULTS: The model results showed that the utiliza-
tion of peginterferon alfa-2a treatment for HBeAg-positive CHB can prolong 0.672 
QALYs, compared to the entecavir treatment. The total cost per patient treated with 
peginterferon alfa-2a was US$28,093, and US$25,768 for patient treated with ente-
cavir. The discounted incremental cost per QALY gained for pegainterferon alfa-2a 
treatment was US$3,461. CONCLUSIONS: The results of the model suggest that 
pegainterferon alfa-2a improves health outcomes in a cost-effective manner compared 
with entecavir in the treatment of HBeAg-positive chronic hepatitis B in China.
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OBJECTIVES: To conduct a cost-utility analysis of rotavirus vaccine (Rotarix®) for 
infants in Japan. METHODS: A Markov model was constructed to analyze costs and 
Quality-Adjusted Life Years (QALYs) from the societal perspective. We captured costs 
and outcomes until infants reached ﬁve years old. In the Markov model, one month 
was set as one cycle. Both costs and utility were discounted at 3 percent annually. 
Based on suggestions from expert of pediatric infectious diseases, various factors have 
relationship with immunological status, such as breastfeeding and communal living, 
were adopted to our model. The health care cost were derived from Japanese data. 
Effectiveness of vaccination was derived from clinical trial in Europe. Various sensitiv-
ity analyses, both univariate and probabilistic ones, were conducted. We used QALY 
for outcome measurement. Quality weight for each status was derived from the foreign 
literature. RESULTS: In the basecase analysis, Rotarix® increased both costs and 
QALYs, compared to no vaccination. Rotarix® would increase costs of JPY 9253 
(US$93, USD1  JPY100). and increase 0.0024 QALY in infants in Japan. ICER for 
Rotarix was JPY3.8 million (US$D38,000) per QALY gained. Sensitivity analyses 
suggested the robustness of the results. When we set threshold for 1QALY to JPY5.0 
million (US$50,000), the probability of the acceptance of Rotarix was 83%. CON-
CLUSIONS: Rotarix® for infants in Japan, is thought to be cost-effective.
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OBJECTIVES: In the past decade, infection with the hepatitis C virus has turned out 
to be a major health threat among speciﬁc risk groups. Given the silent nature, but 
serious long term complications of hepatitis C infection, case ﬁnding is as difﬁcult as 
it is vital. To improve hepatitis C case ﬁnding, the need for public campaigns is 
increasingly recognized. Three pilot campaigns have been performed in The Nether-
lands: a campaign aimed at the general population, the same campaign extended with 
a support programme for primary care and a campaign speciﬁcally aimed at hard drug 
users. The aim of this study is to evaluate cost-effectiveness (from a health care per-
spective) of these campaigns, when performed on a national scale. METHODS: 
Information gained during the pilot studies and estimations for costs for a national 
campaign were used to build a mathematical model to estimate the incremental cost-
effectiveness ratios. The natural history of hepatitis C was described by a previously 
developed Markov model, that was adapted to the current Dutch situation. RESULTS: 
For the ‘support campaign’ the discounted incremental cost per tested person is a326 
with an associated gain of 0.022 QALYs (^8 days). The resulting ICER is a14,980 
per QALY. For the ‘drug users campaign’ the discounted incremental cost per tested 
person is a1960 with an associated gain of 0.168 QALYs. The resulting ICER is 
a11,747 per QALY. CONCLUSIONS: The campaign aimed at the general public 
without support for primary care did not improve case ﬁnding and was therefore not 
cost-effective. Considering a Dutch cut-off point of an ICER of a20,000 as a favour-
able cost-effectiveness ratio, both the campaign accompanied by additional support 
for primary care and the campaign aimed at hard drug users are to be considered a 
cost-effective investment to improve case ﬁnding and prevent future complications of 
hepatitis C.
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OBJECTIVES: To evaluate the cost-utility of pneumococcal conjugate vaccines in 
Germany (societal perspective). METHODS: An age-compartmental, one-year, steady-
state population model was developed to estimate annual incremental cost savings 
(CS) and QALYs gained (QG) for pneumococcal non-typeable  Haemophilus inﬂuen-
zae protein-D conjugate vaccine (PHiD-CV) and 13-valent pneumococcal candidate     
vaccine (PCV-13) compared with PCV-7. Two scenarios were evaluated: one consider-        
ing effectiveness against Streptococcus pneumoniae (Sp) only, another including effec-
tiveness against non-typable Haemophilus inﬂuenzae (NTHi) in acute otitis media 
(AOM) for PHiD-CV. Invasive pneumococcal disease (IPD) serotype-speciﬁc effective-     
ness data were taken from US studies; effectiveness data for pneumonia were derived 
from the PCV-7 Kaiser Permanente trial and for AOM from two randomized Euro-
pean clinical trials. Epidemiological data and utility decrements were taken from 
published literature. DRGs (2008) provided the basis for stationary cost data, while 
ambulatory cost for pneumonia and AOM was estimated by experts. Other parameters 
included: vaccination coverage (90%), discount rate (3%), age-speciﬁc IPD herd 
immunity (30%[18], 19%[18–64], 38%[65]), price parity for all vaccines. 
RESULTS: In the scenario considering effectiveness against Sp only, PCV-13 domi-
nated both PCV-7 (CS: 5.8mna, QG: 260.6) and PHiD-CV (CS: a3.2mn, QG: 159.9). 
In the scenario including effectiveness against NTHi in AOM, PHiD-CV dominated 
both PCV-7 (CS: a9.0mn, QG: 637.1) and PCV-13 (CS: a3.2mn, QG: 376.5). Results 
were robust in both one-way and probabilistic sensitivity analysis. CONCLUSIONS: 
Including effectiveness against NTHi in AOM in the analysis, the protein-D conjugate 
vaccine PHiD-CV is cost saving compared to the CRM conjugate vaccines PCV-7 and 
the candidate vaccine PCV-13.
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OBJECTIVES: This study aims to estimates cost and effectiveness of itraconazole and 
posaconazole in prophylaxis of invasive fungal infections (IFI) patients with neutro-
penia in Spain. METHODS: From the payer’s perspective, a Markov model was 
developed to represent the transition of a neutropenic cohort of patients with prophy-
laxis of IFI through different health states: patient in prophylaxis of IFI, IFI, no-IFI, 
death by IFI and death by some other causes. Efﬁcacy data on incidence of proven or 
probable IFI, survival data and health-state utilities were obtained from published 
studies. Deterministic results were estimated and a probabilistic sensitivity analysis 
was conducted using statistical distributions in order to capture parameter uncertainty 
in the decision model. Treatment costs were obtained from a panel of clinical experts. 
Costs were referred to year 2009 and a time horizon of 1 year was chosen. Results 
were presented as expected cost per quality adjusted life years (QALYs) gained and 
represented in cost-effectiveness acceptability curves (CEACs). RESULTS: In the deter-
ministic analysis, the expected cost per patient was greater in the posaconazole cohort 
(a19,522) in comparison with itraconazole cohort (a19,508). The estimated effective-
ness was the same (0.42 QALY gained) in both cohorts. In the probabilistic analysis 
CEACs showed that the probability that the treatment with itraconazole was more 
cost-effective than the treatment with posaconazole using alternative values for the 
maximum value that the health service would be willing to pay for an additional 
QALY in prophylaxis of IFI was greater in the itraconazole cohort. CONCLUSIONS: 
When itraconazole has been compared to posaconazole we may conclude that the ﬁrst 
one is a dominant strategy. Results from probabilistic sensibility analysis show that 
the choice of optimal strategy is independent on the maximum that the health service 
is prepared to pay per additional QALY gained because itraconazole has a greater 
probability of being cost-effective for all threshold values.
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OBJECTIVES: DUET-1 and DUET-2 are two identically designed, randomized,        
double-blind, placebo-controlled, Phase-III-trials, which have demonstrated superior-
ity of etravirine (ETR) background regimen (BR) (ETR-arm) versus placebo  BR 
(PLAC-arm) in HIV-1-infected, treatment-experienced patients. Hospitalisation events 
and duration of hospital stay were recorded for each patient. The objective of this 
study was to calculate the costs of hospitalisations observed in the DUET trials for 
the German health care setting. METHODS: The number and duration of hospitalisa-     
tions were analyzed at 48 weeks. Hospitalisation rates were analyzed by negative 
binomial regression. Hospital costs in the German setting were calculated by applying 
the German-DRG system for each patient based on individually recorded disease 
characteristics and diagnoses. For all psychiatric admissions, where DRGs are not 
applicable, the ﬁxed daily rate was used (a241/d). RESULTS: A total of 1203 patients  
were included: 599 vs 604 in the ETR- versus PLAC-arms. Numbers (%) of patients 
hospitalised were 105 (17.5%) vs. 139 (23.0%) for ETR-arm vs. PLAC-arm, respec-
tively (p  0.0006). The mean durations of stays for second (13.5d) or subsequent 
hospitalisations (15.6d) were longer than for ﬁrst admission (10.4d) overall, and for 
all stays were longer and therefore more expensive in PLAC-arm (12.3d) vs. ETR-arm 
(11.0d). Patients with baseline-CD4-cell-counts of 50 cells/mm3 had a statistically 
signiﬁcant lower hospitalisation rate in the ETR-arm versus PLAC-arm (p  0.0001). 
Total hospital days observed during the 48-week follow-up period were 1702 vs. 2747 
for ETR-arm vs. PLAC-arm. Calculated total hospital costs were a633.238 (ETR-arm) 
vs. a975,750 (PLAC-arm), resulting in a mean saving for hospitalisation costs of a572 
for each patient treated within the ETR-arm. CONCLUSIONS: At Week 48, ETR    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BR provided a statistically signiﬁcant reduction in overall hospitalisations rates and 
costs versus placebo  BR. Reductions in hospitalisation time indicate signiﬁcant 
savings to the health care system and clinical beneﬁt to the patients.
INFECTION – Patient-Reported Outcomes Studies
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OBJECTIVES: Fixed-dose combination (FDC) products consisting of q2 antiretrovi-
rals in one tablet improve adherence compared to the same agents taken separately. 
The impact of FDC products on adherence to other regimen components has not been 
assessed. We used pharmacy records to evaluate whether an FDC product improves 
HIV patients’ adherence to a 3rd regimen agent. METHODS: Data from 1997–2005 
were taken from IHCIS Managed Care Benchmark Database, a national sample of 30 
health plans covering ^38M lives. We compared adherence to the 3rd regimen com-
ponent among patients with q1 pharmacy claim for the FDC Epzicom (abacavir sulfate 
600 mg  lamivudine 300 mg) versus 2 NRTIs as separate pills (SP). Adherence was 
measured as the medication possession ratio (MPR). Multivariate logistic regression 
compared treatment groups based on the likelihood of achieving q95% adherence, 
with sensitivity analyses across other adherence thresholds. Multivariate linear regres-
sion assessed the effect of treatment group on MPR as a continuous variable. Covari-
ates included age, gender, insurance payer type, year of study drug initiation, presence 
of mental health and substance abuse disorders, and 3rd agent class. RESULTS: The 
sample consisted of 650 FDC and 1947 SP patients. Unadjusted mean adherence to 
the 3rd agent was higher in the FDC than the SP group (0.92 vs 0.85; p  0.0001). 
Adjusting for covariates, FDC patients were 48% and 39% more likely to achieve 
95% and 90% adherence to the 3rd agent, respectively (p  0.05 for each). These 
results did not hold for other MPR speciﬁcations. CONCLUSIONS: For patients 
enrolled in managed care plans, use of an FDC appears to substantially improve 
adherence to a 3rd agent and the likelihood of achieving the accepted standard for 
adherence to HIV therapy of 95%. FDCs may improve overall adherence by increasing 
adherence to both the backbone and the 3rd component of the regimen.
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OBJECTIVES: This study is to assess the hepatitis C (HCV) burdens on health-related 
quality of life (HRQoL) and resource utilization in Europe. METHODS: Data from 
2006 to 2008 National Health and Wellness Survey (NHWS) in France, Germany, 
Italy, Spain, and UK were applied. Responders were representative adults. Those with 
self-reported hepatitis C were categorized as cases. Propensity-matched non-hepatitis 
survey responders were selected as controls based on country, gender, age, education, 
employment, and year of survey. HRQoL was collected from both SF-8/SF-12 and 
Work Productivity Activity Impairment (WPAI) standard instruments. The numbers 
of physician and emergency room (ER) visits were also collected. Conditional logistic 
regression was applied controlling for AIDS/HIV status, health status measured by the 
Charlson Index less hepatitis C, marital status, smoking status, alcohol consumption, 
and body mass index. RESULTS: The ﬁnal sample included 864 cases and 864 closely 
matched controls. Sixty-one percent were male with mean age of 49.8 years. HCV 
patients reported signiﬁcantly impaired HRQoL scores on both SF-8/SF-12 mental 
score and physical score (P  0.01). Work productivity was also reported lower for 
cases although not statistically signiﬁcant due to limited number of employed patients. 
In the six months prior to the survey, HCV patients, compared to controls, were 
 signiﬁcantly more likely to have an ER visit (OR  1.497, 95%CI: 1.092–2.051), sig-
niﬁcantly more likely to visit an internist (OR  2.297, 95%CI: 1.413–3.736), gastro-
enterologist (OR  1.997, 95%CI: 1.285–3.104), nephrologist (OR  3.149, 95%CI: 
1.142–8.682), or other medical specialist (OR  1.434, 95%CI: 1.054–2.050). Overall 
HCV patients reported 2.34 more medical visits than controls (95%CI: 1.1613–
3.5315) in the past six months. CONCLUSIONS: HCV infected patients in Europe 
reported signiﬁcantly lower HRQoL than non-HCV infected subjects, and were more 
likely to have ER and physician visits.
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OBJECTIVES: To evaluate the psychometric properties of the Functional Assessment         
of Human Immunodeﬁciency Virus Infection (FAHI) questionnaire, a 47-item disease-
speciﬁc instrument evaluating Health-Related Quality of Life (HRQL) in Human 
Immunodeﬁciency Virus (HIV) patients, and show its usefulness for the evaluation of 
new antiretroviral therapy. METHODS: Treatment-experienced HIV patients included    
in two independent clinical programmes completed the self-administered FAHI ques-
tionnaire at Baseline and after 24 weeks of treatment. The FAHI questionnaire 
includes ﬁve scales (physical well-being, emotional well-being, functional and global 
well-being, social well-being, cognitive functioning) and a total score, with higher 
scores indicating better HRQL. Psychometric properties of the FAHI questionnaire 
were assessed independently in both trial populations (N  565, 1096). A range of 
minimal important differences (MID) was provided using anchor-based and distribu-
tion-based methods. The link between HRQL and biological endpoints was explored 
by regression analysis. RESULTS: Internal consistency reliability was good, with      
Cronbach’s alphas ranging from 0.72 to 0.94. Most items met both convergent and 
discriminant validity criteria, demonstrating good construct validity of the scores. 
Clinical validity was demonstrated by better FAHI scores, indicating better HRQL for 
patients in earlier HIV stages. Changes in scores were signiﬁcantly linked to the change 
in EQ-5D score, demonstrating their responsiveness. MID ranged from 3.2 to 14 for 
the FAHI Total score. Regression analyses between the FAHI Total score and CD4 
cell count and viral load showed a poor relationships between HRQL and biological 
parameters (r-square 3%). CONCLUSIONS: The FAHI questionnaire demonstrated    
robust psychometric properties in two independent clinical trial populations. The 
assessment of HRQL enabled the detection of changes in patients’ health status not 
revealed by traditional clinical parameters of efﬁcacy.
PIN69
A PATIENT SATISFACTION QUESTIONNAIRE FOR ASSESSING 
PHARMACEUTICAL CARE SERVICES IN NIGERIAN HIV CLINICS
Njilele NA, Ekwunife OI, Ukwe CV
University of Nigeria Nsukka, Nsukka, Enugu State, Nigeria
OBJECTIVES: To develop and validate a questionnaire for assessing patient satisfac-
tion with pharmaceutical care received in Nigerian HIV clinics. METHODS: Ques-
tionnaire’s items were selected from similar published studies and designed as 5-point 
Likert response scale. Face and content validity, feasibility, factorial validity, reliabil-
ity, discriminant and convergent validity were evaluated. The instrument’s feasiblity 
was assessed in a secondary health care facility (St. Charles Borromeo Hospital 
Onitsha) and validated in a tertiary health care facility (University of Nigeria Teaching 
Hospital Enugu). Factor analysis used principal components and varimax rotation. 
Reliability was established using internal consistency with Cronbach’s alpha. Conver-
gent and discriminant validity were determined using Spearman’s rho correlation. 
RESULTS: A self-administered questionnaire with 16 items, 5-point Likert response 
scale and demographic questions was designed. Questionnaire evaluates cumulative 
experience of patients with comprehensive pharmaceutical care practice in pharmacies 
of HIV clinics. Seventy questionnaires were collected for pilot test while four hundred 
questionnaires were retrieved for the validity test. Factor analysis resulted in four 
factors: relationship, patient counseling, drug information and patient care, with a 
cumulative variance of 56.7%. Cronbach’s alpha for the whole questionnaire was 
0.85, and 0.81, 0.66, 0.67 and 0.72 for the 4 factors, respectively. Four items used 
for convergent and discriminant validity showed convergence between the related 
items and variance between the unrelated items. CONCLUSIONS: The questionnaire 
developed can be a reliable and valid instrument to assess patient satisfaction with 
pharmaceutical care in HIV clinics in Nigeria. Further research is needed to re-validate 
the instrument.
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OBJECTIVES: During the clinical development of a new intradermal inﬂuenza vaccine          
given using a microinjection system, in parallel with the conventional evaluation of 
vaccine reactogenicity, perception and acceptability of injection site reactions (ISR) 
were assessed using the VAPI© self-administered questionnaire developed and vali-
dated as previously described (Chevat et al, Health and Quality of Life Outcomes 
2009, 7:21). METHODS: The questionnaire was speciﬁcally developed and validated       
according to recommended methods to assess vaccinees’ perception of ISR. It was 
completed 21 days after intradermal or intramuscular vaccination by elderly and non-
elderly participants in two European, randomised, controlled, phase 3 trials. It was 
divided into 4 dimensions: “bother” (6 items), “arm movement” (4 items), “sleep” 
(4 items), “acceptability” (2 items), and 5 individual items: anxiety before and after 
vaccination, bother by pain during injection, satisfaction with injection system and 
willingness to be vaccinated again. Scores range from 1 to 5 (1 being the most favour-
able opinion). RESULTS: Of the 5,562 trial participants, 5,305 returned the question-        
naire with at least one item completed. Mean scores were low (a1.68 in non-elderly, 
a1.48 in elderly) in both vaccine groups, indicating that ISR did not bother partici-
pants or affect their sleep or arm movement (at least 75% were not at all affected). 
In the ID group, among those who answered the questions, 96% of non-elderly and 
97% of elderly participants considered ISR caused by vaccination as being “totally” 
or “very” acceptable; 96% of both non-elderly and elderly participants were “very 
satisﬁed” or “satisﬁed” with the injection system; and 85% of non-elderly and 89% 
of elderly participants wanted to be vaccinated again. CONCLUSIONS: ISR were  
well accepted by participants, and were generally not a cause for concern. The level 
of satisfaction of the participants with the injection system was high, as was the 
willingness to be vaccinated again.
